Three years after it was formed as a spinout of Japanese drugmaker Takeda, Phathom Pharmaceuticals has racked up its first FDA approvals, and claimed a sizeable $260 million in new financing to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback